Summary
Racepinephrine has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Heart Failure would be drug repurposing rather than first-in-human development. This does not mean it is approved for Heart Failure. ClinicalTrials.gov lists 8 registered trials linking Racepinephrine to Heart Failure: 3 are currently recruiting; 2 have completed; 3 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT07281014). The largest enrolment is 5000 participants (NCT04278404). Registration activity spans 2003 to 2026. No published literature item is linked to Racepinephrine and Heart Failure in the OSMF database yet, so the record rests on registry entries alone. Registry entries describe intent to study, not outcomes.
The RepurpOS disease-intelligence file for Heart Failure ranks 616 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Annual mortality ~22% on standard care; only 5-11% of HFrEF patients achieve normalisation of ejection fraction (HFrecEF) with GDMT; HFpEF has no disease-modifying therapy.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 43.0 (trials 23.0, literature 0.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 3 recruiting, 0 active / not yet recruiting, 2 completed, 3 other |
| Linked publications | 0 |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | agonist |
| Data sources | DGIdb |
| Linked via biomarker / target | ADRB3 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT07281014 | Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing 2026 | recruiting | Phase 4 | 20 |
| NCT00446017 | The Effects of Adrenaline and Milrinone in Patients With Myocardial Dysfunction After CABG 2003 | completed | Phase 3 | 60 |
| NCT02617602 | Goal Directed Hemodynamic Management of Acute Heart Failure After Cardiac Surgery in Children 2015 | status unknown | Phase 3 | 40 |
| NCT02161445 | Systolic Time Intervals in the Diagnosis of Heart Failure in Emergency Departement 2012 | completed | Not applicable | 530 |
| NCT04278404 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) 2020 | recruiting | Not applicable | 5,000 |
| NCT04682483 | Cardiogenic Shock Working Group Registry 2017 | recruiting | Not applicable | 5,000 |
| NCT05202938 | eMESH Struct. 2022-23 2022 | status unknown | Not applicable | 32 |
| NCT05782075 | Biological Monitoring by a Nurse for Heart Failure Patients. 2023 | status unknown | Not applicable | 100 |
Published literature
No publication is linked to this pair yet.
Mechanism and notes
Recorded mechanism or class: agonist.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target ADRB3. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Racepinephrine approved for Heart Failure?
Racepinephrine has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Heart Failure would be drug repurposing rather than first-in-human development. This does not mean it is approved for Heart Failure. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Racepinephrine in clinical trials for Heart Failure?
ClinicalTrials.gov lists 8 registered trials linking Racepinephrine to Heart Failure: 3 are currently recruiting; 2 have completed; 3 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT07281014). The largest enrolment is 5000 participants (NCT04278404). Registration activity spans 2003 to 2026.
What does the evidence show for Racepinephrine in Heart Failure?
Racepinephrine has 2 completed registered trials for Heart Failure but no linked publication, which usually means results are unpublished, pending, or not yet matched to this record. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target ADRB3. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.